{"id":"NCT00829010","sponsor":"GlaxoSmithKline","briefTitle":"Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.","officialTitle":"Primary and Booster Vaccination Course in Human Immunodeficiency Virus (HIV) Infected Infants, HIV Exposed Uninfected Infants and Unexposed Uninfected Infants Receiving the Pneumococcal Vaccine GSK 1024850A.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02-17","primaryCompletion":"2011-06-13","completion":"2012-06-27","firstPosted":"2009-01-26","resultsPosted":"2012-07-06","lastUpdate":"2018-08-17"},"enrollment":489,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal vaccine GSK1024850A","otherNames":[]},{"type":"BIOLOGICAL","name":"Tritanrix-HepB/Hib","otherNames":["DTPw-HBV/Hib"]},{"type":"BIOLOGICAL","name":"measles","otherNames":[]},{"type":"BIOLOGICAL","name":"Rotarix","otherNames":["HRV","Human rotavirus"]},{"type":"BIOLOGICAL","name":"Local OPV","otherNames":["oral poliovirus vaccine"]}],"arms":[{"label":"HIV+/+ Group","type":"EXPERIMENTAL"},{"label":"HIV+/- Group","type":"EXPERIMENTAL"},{"label":"HIV- (3+1) Group","type":"EXPERIMENTAL"},{"label":"HIV- (EPI) Group","type":"EXPERIMENTAL"},{"label":"HIV- (2+1) Group","type":"EXPERIMENTAL"}],"summary":"The purposes of this study:\n\n* To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants following a 3-dose primary vaccination at 6, 10 and 14 weeks of age and following booster vaccination at 9-10 months of age.\n* To evaluate the immunogenicity, safety and reactogenicity of pneumococcal vaccine GSK1024850A in HIV unexposed uninfected infants receiving either a 3-dose primary vaccination according to the EPI vaccination schedule at 6, 10 and 14 weeks of age with or without booster vaccination at 9-10 months of age or a 2-dose primary vaccination at 6 and 14 weeks of age followed by booster vaccination at 9-10 months of age.\n* This study also aims to assess the impact of the pneumococcal vaccine GSK1024850A on nasopharyngeal carriage of S. pneumoniae and H. influenzae up to 24 months of age in all study participants.","primaryOutcome":{"measure":"Number of Subjects With Anti-pneumococcal Vaccine Serotype Antibody Concentrations Equal to or Above 0.20 Microgram Per Millilitre (Âµg/mL).","timeFrame":"1 month following primary immunization (post-Dose 3 at Month 3 for the HIV+/+ Group, HIV+/- Group, HIV- (3+1) Group, HIV- (3+0) Group and post-Dose 2 at Month 3 for the HIV- (2+1) Group)","effectByArm":[{"arm":"HIV+/+ Group","deltaMin":69,"sd":null},{"arm":"HIV+/- Group","deltaMin":90,"sd":null},{"arm":"HIV- (3+1) Group","deltaMin":93,"sd":null},{"arm":"HIV- (3+0) Group","deltaMin":94,"sd":null},{"arm":"HIV- (2+1) Group","deltaMin":96,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":13},"locations":{"siteCount":1,"countries":["South Africa"]},"refs":{"pmids":["33245004","32035706","28425818","28079828"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":83},"commonTop":["Pain","Irritability","Swelling","Redness","Drowsiness"]}}